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Edited by Jesus AvilaAbstract Muscle mass is regulated by a wide range of hor-
monal and nutritional signals, such as insulin and IGF. Tuberous
sclerosis complex (TSC) is an inherited hamartoma disease with
tumor growth in numerous organs. TSC is caused by mutation in
either TSC1 or TSC2 tumor suppressor genes that negatively
regulate insulin-induced S6K activation and cell growth. Here
we report that expression of human TSC1 (hTSC1) in mouse
skeletal muscle leads to reduction of muscle mass. Expression
of hTSC1 stabilizes endogenous TSC2 and leads to inhibition
of the mTOR signaling. The hTSC1-mTSC2 hetero-complex
and its downstream components remain sensitive to insulin stim-
ulation and nutrition signals. This study suggests that an increase
in the steady state level of resident TSC1–TSC2 complex is suf-
ﬁcient to reduce muscle mass and cause atrophy.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Transgenesis1. Introduction
Skeletal muscle atrophy accompanies various diseases, such
as cancer, diabetes and AIDS [1]. Muscle atrophy could be in-
duced by deregulation of diﬀerent signaling pathways, includ-
ing interleukin-1 (IL-1), tumor necrosis factor (TNF) and
insulin/insulin-like growth factor (IGF) signaling, which lead
to reduced protein synthesis or activated protein degradation
[2–7]. Insulin/IGF signaling is one of the best-understood sys-
tems in growth regulation. Suppression of its downstream reg-
ulator mammalian target of rapamycin (mTOR), a positive
regulator of protein synthesis, has been suggested to cause
skeletal muscle atrophy [4–7]. Mice lacking both AKT1 and
AKT2, the downstream targets of insulin/IGF, have impaired
mTOR activity and about 50% reduction in muscle mass [6].
Mice without ribosomal protein S6 kinase 1 (S6K1), a positive
protein synthesis regulator downstream of mTOR, also display
20% reduction in muscle size without obviously aﬀecting the
number and type of muscle ﬁbers [7].
Tuberous sclerosis complex (TSC) is an autosomal disorder
characterized as benign tumors in multiple organs. The disease*Corresponding author. Fax: +86 21 6564 3770.
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suppressor genes [8]. The TSC1–TSC2 complex has been char-
acterized in both Drosophila and mammals as a negative regu-
lator of insulin/IGF induced S6K activation [9–12]. Germline
disruption of TSC1 or TSC2 leads to embryonic lethality, dem-
onstrating a general requirement for TSC genes in early deve-
lopment [13]. The C-terminal of TSC2 proteins contains a
domain homologous to the GAP domain of Rap GTPase-acti-
vating protein (Rap GAP), which is responsible for the negative
regulation of Rheb small GTPase and mTOR [14–16]. TSC2
proteins are suggested to be functional in a stable complex with
TSC1 proteins through their coiled-coil domains [17,18]. This
complex prevents ubiquitin-dependent degradation of TSC2
[18]. It can be destabilized by AKT1 dependent phosphoryla-
tion of TSC2, a process regulated by a kinase cascade origi-
nated from extracellular insulin/IGF molecules [9–11,19,20].
Cellular energy and nutrition levels regulate cell growth, cell
size, and cell survival. Nutrition deprivation activates AMP-
activated protein kinase (AMPK) in cultured mammalian cells,
which in turn phosphorylates TSC2 on the T1227 and S1345
residues. AMPK phosphorylated TSC2 suppresses the activity
of mTOR-S6K cascade. In S6K1 knockout mice, skeletal mus-
cle mass fails to respond to altered nutrition conditions, fur-
ther suggesting a critical role for AMPK-TSC-mTOR in
mediating nutrition signals [7,21,22].
To further understand the role of TSC genes in regulating
muscle mass in vivo, we produced transgenic mice ectopically
expressing hTSC1 in the skeletal muscle. These mice showed
reduced muscle mass but otherwise were viable and fertile.
Reduction of muscle mass is correlated with an increase of sta-
ble TSC2, presumably through its interaction with hTSC1 pro-
teins. We further show that insulin and nutrition signals
remain eﬀective in regulating TSC1–TSC2 complex activity
and the downstream events such as activation of S6K in the
transgenic mice. Thus, hTSC1 transgenic mice represent an
animal model for muscle atrophy, in which the muscle retains
relatively normal response to insulin signaling.2. Materials and methods
2.1. Transgenic mice
The 3.3 kbMCK promoter [23] was excised with EcoRI/XbaI and li-
gated into NotI/XbaI sites of pBluescript II KS+ vector. Myc-tagged
full-length human TSC1 cDNA was then cloned into the XbaI site withblished by Elsevier B.V. All rights reserved.
Fig. 1. MCK-driven hTSC1 is preferentially expressed in mouse
skeletal muscle. (A) The MCK-hTSC1 transgenic construct. A 3.5 kb
human TSC1 cDNA (hTSC1) was fused in frame with a 3· myc tag
sequence at the 5 0 end and placed between the 3.3-kb MCK promoter
and the 2.1 kb human growth hormone gene fragment containing the
polyadenylation signal (hGH pA). (B) Expression pattern of hTSC1 in
various organs (top panel) and diﬀerent muscles (bottom panel).
Transgene expression level was detected with anti-myc antibody.
Amount of loaded proteins was judged by Coomassie blue staining or
anti-tubulin antibody staining. H, heart; L, liver; S, spleen; K, kidney;
TA, tibialis anterior; EDL, extensor digitorum longus; Sl, soleus; WT,
TA sample from a wild type littermate. (C) Western blot shows
transgene expression in TA muscles from diﬀerent transgenic lines.
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hormone gene was inserted between the SpeI/XhoI sites to provide
polyadenylation signal (hGH polyA) [24]. The transgene cassette was
linearized by BssHII, puriﬁed by agarose gel and microinjected into
fertilized eggs from FVB/NJ mice. Transgenic oﬀspring was identiﬁed
by a 996-bp PCR product with the following primers: MCK5:
5 0-CGAGCTGAAAGCTCATCTGCTCTCAGGG-30; T1-3: 5 0-TA-
ATTCCGGATGAATTCGCACATGCTCC-3 0. Animals were main-
tained on a 12/12 light/dark cycle and were allowed free access to food
and water. For insulin stimulation test, eight-week-old mice were
fasted overnight before receiving intraperitoneal (I.P.) injection of
insulin next morning. Ten minutes after injection, tibialis anterior
(TA) muscles were rapidly removed from sacriﬁced mice and processed
for Western blot exactly as described below. For starvation and re-
feeding experiments, ﬁve-week-old male mice were deprived of food
for 2 days and then allowed free access to food and water for two days
before analysis [7].
2.2. Histology
TA and extensor digitorum longus (EDL) muscles of 8-week-old
male mice were weighed and embedded in OCT media (Leica CM)
for frozen section. 7 lm thick transverse sections were collected and
stained with haematoxylin/eosin solution (Sigma) to determine muscle
and ﬁber size, or with NADH solution to distinguish fast and slow
muscle ﬁbers. Pictures were taken with a Leica dissecting microscope
and a DC300 camera. Section areas were measured with Adobe Photo-
shop. Fiber size and ﬁber type were determined based on at lease 200
ﬁbers counted in each muscle.
2.3. Western blot
Protein extraction was prepared with the RIPA lysis buﬀer (Santa
Cruz) according to manufacturer’s instruction and quantiﬁed with
the BCAe Protein Assay Kit (Pierce). Equal amounts of samples were
separated by SDS/PAGE, transferred onto PVDF membranes (Milli-
pore), and immunoblotted following standard protocols. Quantitative
analysis was carried out with NIH ImageJ.
Goat anti-Myc antibody (Santa Cruz) was used to detect transgene
expression. Rabbit anti-p-S6K (T389) antibody (Cell Signaling) was
used to detect phosphorylation of Thr 389 residue of S6K proteins,
while rabbit anti-S6K antibody (Cell Signaling) was used to determine
total S6K proteins. Tubulin level usually served as loading control and
was determined by Goat anti-tubulin antibody (Santa Cruz). Rabbit
anti-TSC2 antibody (see acknowledgements) was used to detect endog-
enous mTSC2 proteins. HRP-conjugated bovine anti-goat antibody
and anti-rabbit antibody were purchased from Santa Cruz.2.4. Quantitative real-time RT-PCR
Total RNA extraction and reverse transcription was carried out with
TRIzol (Invitrogen) and 9-bp random primers (Takara), respectively.
Quantitative PCR was performed with the SYBRGreen PCR Master
Mix system (ABgene) on an Mx3000p real-time PCR machine (Strata-
gene).
2.5. Statistical analyses
Results were expressed as the means ± S.D. Statistical signiﬁcances
of body weight, organ weight, and real-time results were determined
using unpaired Student’s t-test. Statistical signiﬁcances of muscle size,
ﬁber size and ﬁber type were determined using unpaired Student’s t-
test and two-tailed Z test. P < 0.001 is considered statistically signiﬁ-
cant in this study.3. Results
3.1. Transgenic expression of hTSC1 in skeletal muscle
To investigate the function of TSC1–TSC2 complex in
mouse skeletal muscle, we generated transgenic mice that ex-
pressed hTSC1 cDNA driven by the promoter of mouse mus-
cle creatine kinase (MCK) gene (Fig. 1A). Transgenes driven
by MCK promoter express preferentially in skeletal muscle,
with a higher level in fast-ﬁber enriched muscles, such asEDL, than in slow-ﬁber enriched muscles, such as soleus.
However, a low-level leaky expression in cardiac muscle was
also reported [23,25]. We produced 11 independent MCK-
hTSC1 transgenic lines and characterized three of them (F13,
F37 and F38) in this study. Consistent with previous studies
of the MCK promoter, the hTSC1 transgene was found highly
expressed in skeletal muscle such as tibialis anterior (TA).
Among all other major organs analyzed, only heart showed
a low-level transgene expression. Further analysis demon-
strated that soleus expressed less hTSC1 proteins than EDL
did (Fig. 1B). The level of hTSC1 expression in line F38 is
96 ± 21% of that in line F37 (P = 0.37), while hTSC1 expres-
sion in line F13 is only 26 ± 12% of that in line F37
(P < 0.001) (Fig. 1C).
3.2. The transgenic mice display skeletal muscle atrophy
All three transgenic lines had normal physical appearance at
birth. However, F37 mice and F38 males exhibited reduced
body weight than their wild type littermates since four to ﬁve
weeks after birth (Fig. 2A). At the age of eight weeks, F37
males and females were 3.0 g (12.2%) and 2.0 g (9.8%) lighter
than their wild type littermates, respectively, while F38 males
Fig. 2. Ectopic expression of hTSC1 causes skeletal muscle atrophy in mice. (A) Body weight reduction in transgenic mice. (B) Muscle size reduction
in transgenic mice measured with H&E staining of cross-sections of TA and EDL from adult male mice. Left panel showed the section from a F37
transgenic mouse and its wild type littermate, bar = 1 mm. Quantiﬁcation of diﬀerent lines is shown in the right panel. (C) TA ﬁber size reduction in
transgenic mice. Left panel showed the H&E staining of the cross-section of TA from a F37 transgenic male mouse and its wild type littermate,
bar = 50 lm. Quantiﬁcation of diﬀerent lines is shown at the right panel. (D) Size reduction of fast ﬁbers and slow ﬁbers in transgenic mice. NADH
staining of the cross-section of TA from adult male mice was performed to measure the average size of diﬀerent ﬁbers. (E) Composition of slow (type
I) ﬁbers and fast (type II) ﬁbers did not change in transgenic mice. TA muscles from adult F37 transgenic males and their wild type littermates were
analyzed. Tg, transgenic mice; WT, wild type littermates; n, number of the samples, error bar shows the standard deviation; *P < 0.001.
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F13 showed no signiﬁcant body weight reduction (Fig. 2A
and data not shown).
We next investigated whether the body weight reduction was
mainly due to the loss of muscle mass. Signiﬁcant decrease in
muscle mass of both TA and EDL was observed in F37 miceand F38 males (P < 0.001, Table 1). In line F13, muscle weight
reduction was approximately 8% (P < 0.005, data not shown).
A less dramatic weight reduction was also observed in heart,
liver, spleen, and kidney of the transgenic mice (Table 1).
These results indicate that muscle mass reduction is a major
contributor to weight loss in the transgenic mice.
Table 1
Organ weight of wild type and transgenic mice
Heart (mg) Liver (mg) Spleen (mg) Kidney (mg) TA (mg) EDL (mg) Body weight (g)
F37 Male
WT (n = 16) 123.2 ± 15.2 1388.2 ± 187.4 98.6 ± 14.0 212.4 ± 31.1 44.8 ± 4.5 9.3 ± 1.4 24.6 ± 1.9
Tg (n = 9) 111.2 ± 9.0# 1263.1 ± 166.7 92.5 ± 7.8 194.7 ± 21.1 32.4 ± 2.4* 7.2 ± 1.6* 21.6 ± 1.1*
F37 Female
WT (n = 12) 96.1 ± 6.8 1061.9 ± 144.6 100.1 ± 11.0 142.3 ± 12.0 38.2 ± 3.2 8.2 ± 0.6 20.4 ± 1.1
Tg (n = 7) 101.5 ± 10.4 1051.3 ± 113.7 99.2 ± 17.3 129.7 ± 17.7 29.4 ± 1.7* 6.7 ± 0.4* 18.4 ± 1.1*
F38 Male
WT (n = 8) 119.0 ± 11.2 1252.2 ± 90.3 95.4 ± 5.5 195.8 ± 17.5 42.7 ± 1.8 9.3 ± 0.7 24.3 ± 0.9
Tg (n = 10) 109.4 ± 7.3 1207.9 ± 75.5 91.9 ± 10.2 190.7 ± 14.1 33.9 ± 1.5* 7.6 ± 1.0* 21.8 ± 1.0*
Eight-week-old mice and their wild type littermates were analyzed. Data are presented as means ± S.D.
Data of transgenic animals were also compared with those of wild type individuals to calculate the P values. *, P < 0.001; #, P = 0.042; unmarked,
P > 0.05.
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further examined by histological analysis. In F37 and F38 male
mice, the combined cross-section of TA and EDL displayed a
23% and 20% reduction in size, respectively (Fig. 2B). Corre-
spondingly, the average of ﬁber size in TA had a 19% and
17% reduction, respectively (Fig. 2C). Although both slow
(type I) and fast (type II) muscle ﬁbers showed smaller sizes
in these two lines, the change of fast ﬁbers was more severe
than that of slow ﬁbers (P < 0.001, Fig. 2D). This was likely
due to higher transgene expression in fast ﬁbers driven by
the MCK promoter. F13 males displayed about 12% decrease
in both muscle and ﬁber size (data not shown). These observa-
tions support that hTSC1 expression resulted in skeletal mus-
cle atrophy in a dosage-dependent manner. Consistent with
previous studies in AKT1 transgenic and S6K1 mutant mice,
analysis of ﬁber type composition did not reveal any signiﬁcant
changes in hTSC1 transgenic mice when compared with wild
type littermates (Fig. 2E) [7,26].Fig. 3. Ectopic expression of hTSC1 stabilizes endogenous TSC2
proteins. (A) Western blot of TAs from three F37 transgenic
individuals and their wild type littermates. Anti-myc antibody was
used to detect transgene expression. Anti-TSC2 antibody shows
endogenous TSC2 protein level. Tubulin level served as the loading
control. (B) TSC2 mRNA levels were not changed in transgenic
animals. TSC2 mRNA was quantiﬁed by real-time RT-PCR. TA
samples were from F37 transgenic males and their wild type
littermates. Each group has three individuals. Results were normalized
with endogenous GAPDH mRNA level. Error bar shows the standard
deviation.3.3. Increased endogenous TSC2 protein level in hTSC1
transgenic mice
TSC1 and TSC2 form a functional complex to suppress insu-
lin/IGF signaling cascade. Separation of TSC1 from TSC2
leads to ubiquitin-dependent degradation of the latter [18].
To study the mechanism of skeletal muscle atrophy in hTSC1Fig. 4. TSC hetero-complex is regulated by insulin signaling. (A)
Insulin stimulation decreased TSC2 protein levels and increased S6K
phosphorylation in TA muscle. TA samples from adult female mice
were used for Western blot. Each fasted mouse was stimulated with
PBS containing 0, 0.5, or 1.0 IU of insulin as described above. Free
feeding mice (Con.) were also sampled as the control. (B) S6K and S6
phosphorylation after insulin stimulation. All procedures were the
same as in (A), except 5 IU of insulin was used for each mouse.
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levels of endogenous TSC2 in TA muscles. Despite of in-
creased protein level (Fig. 3A), the abundance of TSC2
mRNA in the muscle sample of F37 transgenic mice was not
aﬀected (Fig. 3B). Similar results were obtained from F38 mice
(data not shown). This observation implies that hTSC1 can
stabilize endogenous mouse TSC2 (mTSC2) in vivo and the
hTSC1-mTSC2 hetero-complex may be responsible for the
reduction of muscle mass in the transgenic mice.
3.4. The TSC1–TSC2 complex is regulated by the insulin signal
Activity of the TSC1–TSC2 complex is regulated by AKT
and its upstream growth signals. In mammalian cells and
Drosophila insulin/IGF signals trigger AKT mediated phos-
phorylation of TSC2, and consequently inhibit functions of
the TSC1–TSC2 complex. The TSC1–TSC2 complex is able
to suppress the phosphorylation of Thr 389 in S6K, which is
an essential step to further phosphorylate S6 (Fig. 4A)
[10,11]. We evaluated the eﬀect of insulin signaling on the sta-
bility of mTSC2 in fasted hTSC1 transgenic mice. Insulin stim-
ulation resulted in degradation of most endogenous mTSC2 in
both control and transgenic individuals (Fig. 4A). Further-
more, phosphorylation of S6K and S6 in response to insulin
stimulation occurred similarly in both hTSC1 transgenic and
the wild type littermates (Fig. 4A and B). These results indicate
that the activity of hTSC1-mTSC2 hetero-complex is regulatedFig. 5. Skeletal muscle of the transgenic mice responds to nutrition
condition alterations. (A) TA and EDL mass changes after starvation
and re-feeding processes. (B) Phosphorylation of S6K during starva-
tion and re-feeding. Western blots of protein extracts from TA muscles
were shown. Tg, transgenic group; WT, wild type littermates; Con, free
fed mice; St, starved mice; Rf, re-fed mice. #P < 0.05; *P < 0.001.by insulin signal in a manner similar to endogenous mouse
TSC1–TSC2 complex.3.5. Nutrition regulates the TSC1–TSC2 complex in the
transgenic mice
The TSC1–TSC2 complex is able to mediate cellular nutri-
tion responses. To determine whether the hetero-complex is
also subject to nutrition regulation, we evaluated the response
of skeletal muscle to starvation and re-feeding conditions.
Both transgenic and wild type littermates lost about 30% of
the body weight after 48-h starvation, and recovered to
approximately 90% of the original weight after re-feeding for
another 48 h (data not shown). In both groups of mice, TA
and EDL muscle mass showed the same trend of reduction
and recovery responding to the starvation and re-feeding pro-
cesses, respectively (Fig. 5A). Both transgenic and wild type lit-
termates had phosphorylated S6K level increased following
nutrition recovery (Fig. 5B). These data indicate that the
hTSC1-mTSC2 hetero-complex could respond to changes in
nutrition conditions.4. Discussion
TSC1 and TSC2 proteins can form stable complexes and
function as suppressors of insulin/IGF pathway in Drosophila
and cultured mammalian cells [9,11,14,19,20]. Inhibition of
insulin/IGF signaling in mouse skeletal muscle could cause
muscle atrophy [6,7,27,28]. In our study, ectopic expression
of wild type hTSC1 enhanced the intracellular level of TSC2
proteins and caused a reduction in muscle mass. Considering
the high degree of similarity among mammalian TSC protein
sequences and functional conservation across species, these re-
sults suggested that the hTSC1 transgene induced an increase
of functional TSC1–TSC2 complexes in muscle cells.
Skeletal muscle constitutes approximately 30% of total body
mass [29]. In our experiments, hTSC1 expression in the skeletal
muscle leads to more than 20% reduction of the muscle mass
(Table 1), which accounts for nearly two thirds of total body
weight loss (about 10%) in corresponding lines. In addition
to muscle atrophy, a less dramatic weight reduction was also
observed in other major organs (Table 1). This is not unex-
pected since skeletal muscle also takes part in energy and pro-
tein metabolism in vivo. Thus, muscle mass changes may
induce metabolic alterations and weight reductions in other tis-
sues.
In addition to growth control, insulin/IGF signaling is
known to be involved in regulating glucose homeostasis. Inhi-
bition of this pathway in mouse skeletal muscle usually causes
impaired glucose homeostasis [27,28]. However, hTSC1 trans-
genic mice showed normal level of blood glucose in either fast-
ing or random-feeding conditions, and behaved normally in
glucose and insulin tolerance tests (data not shown). These re-
sults imply that increase of TSC1–TSC2 complex level in skel-
etal muscle does not aﬀect glucose homeostasis.
In contrast to the above model that puts TSC proteins
downstream of insulin signaling, a parallel model suggesting
independent function of TSC proteins and insulin in regulating
cell growth has also been proposed in Drosophila [9,30]. Our
data showed that the level of TSC2 protein in skeletal muscle
is subject to insulin regulation in both transgenic and wild type
5626 M. Wan et al. / FEBS Letters 580 (2006) 5621–5627mice (Fig. 4A). This result supports the linear relationship be-
tween insulin and TSC1–TSC2 complex.
TSC proteins suppress insulin-stimulated S6K activity with a
dosage-dependent manner in cultured mammalian cells [11]. In
hTSC1 transgenic mice, we observed normal activation of S6K
after insulin stimulation even though TSC1–TSC2 complex
is increased (Fig. 4A and B). Transiently transfected cells are
likely to produce a much higher level of TSC proteins than
in the transgenic mice. In addition, TSC1 and TSC2 were co-
transfected in the cell culture experiment whereas only TSC1
was used in producing the transgenic mice. These diﬀerences
may lead to the resistance to insulin mediated TSC protein
degradation in cultured cells but not in the transgenic mice.
S6K is a positive regulator of protein synthesis. It needs to be
phosphorylated to be functional. However, S6K phosphoryla-
tion in mouse skeletal muscle is too low to be determined
accurately under normal conditions. Thus we used starvation-
refeeding assay to stimulate S6K phosphorylation. Although
increased phosphorylation of S6K was observed in both trans-
genic and wild type littermates after refeeding, we did notice an
approximately 36% reduction of phosphorylation in the trans-
genic group (Fig. 5B). Block of S6K activation, although not as
dramatic as reported in the tissue culture system, may account
for the reduced muscle mass in transgenic animals. This is
consistent with the observations in Drosophila that S6K aﬀects
cell mass through insulin-TSC signaling [9,10].
An important observation is that muscle mass change of
hTSC1 transgenic mice in the starvation-refeeding test is in
proportion to that of the wild type mice (Fig. 5A). This indi-
cates that muscle mass is subject to regulation by an intrinsic
genetic factor which diﬀerentiates the transgenic mice from
the wild type controls. Intracellular TSC1–TSC2 complex
has been shown to control cell size in a cell autonomous man-
ner [9,10]. Mutations in Drosophila and mammalian TSC1 or
TSC2 result in a cell autonomous increase in cell size, while
overexpression of TSC1 and TSC2 leads to the opposite eﬀect
[9,10,21,31,32]. Our result is consistent with the idea that the
level of TSC1–TSC2 complex is involved in setting the ﬁnal
size of muscle ﬁbers.
In conclusion, our studies suggest that the TSC1–TSC2 com-
plex plays an important role in determining the ﬁber size of
skeletal muscles in mice. An increase of the TSC1–TSC2 com-
plex leads to reduction of muscle mass and atrophic pheno-
types. In addition to explore the utility of TSC1 expression
as animal models for muscle atrophy, it would be interesting
to investigate whether elevated TSC1–TSC2 complex level also
responsible for a subset of muscle atrophy among human pop-
ulation.
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